uploads/2018/03/medic-563423_1920.jpg

Ionis Pharmaceuticals Stock as of March 27, 2018

By

Updated

Ionis Pharmaceuticals

Ionis Pharmaceuticals (IONS) is one of the leading RNA[1. ribonucleic acid]-targeted therapeutics development companies. It develops new best-in-class drugs for life-threatening diseases and markets the approved products in collaboration with other pharmaceutical companies.

The above chart compares the past week’s returns for Ionis Pharmaceuticals, some other pharmaceutical companies, and the First Trust NYSE Arca Biotechnology ETF (FBT).

Article continues below advertisement

Ionis stock performance

The major global markets weakened over the last few days over concerns of a possible US-China trade war. Ionis stock has fallen 6.9% over the last week. However, it rose 2.6% to close at $48.99 on March 26, 2018, compared to $47.74 on March 23, 2018.

Ionis stock has fallen 4% over the last month, while it has increased 25.7% over the last year. The stock is trading 3.8% lower than its 30-day simple moving average.

Comparison with other stocks and ETF

The First Trust NYSE Arca Biotechnology ETF (FBT) reported a price decrease of 1.8% over the last week. However, it rose 2.8% to close at $136.42 on March 26, 2018, compared to $132.67 on March 23, 2018.

FBT has risen 31.5% over the last year. It holds 3.2% of its total investments in Ionis Pharmaceuticals (IONS), 3% in Incyte (INCY), 2.8% in Celgene (CELG), and 3% in BioMarin Pharmaceutical (BMRN).

Over the last week, Incyte (INCY) stock has increased marginally by 0.1%, closing at $86.37 on March 26, 2018. That was a 4% increase from the closing price of $83.06 on March 23, 2018.

Celgene (CELG) stock has fallen 1.5% over the last week. Its closing price was $87.17 on March 26, 2018, which was a 2.6% increase compared to the closing price of $84.98 on March 23, 2018.

BioMarin Pharmaceutical (BMRN) stock has fallen 4.2% over the last week. Its closing price was $80.30 on March 26, 2018, which was a 1.8% increase from the closing price of $78.84 on March 23, 2018.

Advertisement

More From Market Realist